Association of Exon 14 of the SOX6 Gene Sequence Variations with Response to Hydroxyurea Therapy in Patients Carrying Non Transfusion-Dependent Thalassemia

References

• Pourfarzad F, von Lindern M, Azarkeivan A, et al. Hydroxyurea responsiveness in β-thalassemic patients is determined by the stress response adaptation of erythroid progenitors and their differentiation propensity. Haematologica. 2013;98(5):696–704.
   PubMed Web of Science ®Google Scholar
• Lanzkowsky P. Manual of Pediatric Hematology and Oncology. Amsterdam (The Netherlands): Elsevier; 2010.
   Google Scholar
• Cao A. Diagnosis of β-thalassemia intermedia at presentation. Birth Defects Orig Artic Ser. 1988;23(5b):219–226.
   PubMedGoogle Scholar
• Akinsheye I, Alsultan A, Solovieff N, et al. Fetal hemoglobin in sickle cell anemia. Blood. 2011;118(1):19–27.
   PubMed Web of Science ®Google Scholar
• Li J, Lai Y, Luo J, et al. SOX6 Downregulation induces γ-globin in human β-thalassemia major erythroid cells. Biomed Res Int. 2017;2017:9496058.
   PubMed Web of Science ®Google Scholar
• Atashi A, Soleimani M, Kaviani S, et al. In vitro induction of fetal hemoglobin in erythroid cells derived from CD133 cells by transforming growth factor-b and stem cell factor. Iran J Biotechnol. 2008;6(3):157–163.
   Google Scholar
• Keikhaei B, Yousefi H, Bahadoram M. Clinical and haematological effects of hydroxyurea in β-thalassemia intermedia patients. J Clin Diagn Res. 2015;9(10):OM01–OM03.
   PubMedGoogle Scholar
• Fitzhugh CD, Hsieh MM, Allen D, et al. Hydroxyurea-increased fetal hemoglobin is associated with less organ damage and longer survival in adults with sickle cell anemia. PLoS One. 2015;10(11):e0141706.
   PubMed Web of Science ®Google Scholar
• Atweh G, Loukopoulos D. Pharmacological induction of fetal hemoglobin in sickle cell disease and β-thalassemia. Semin Hematol. 2001;38(4):367–373.
   PubMed Web of Science ®Google Scholar
• Ware RE, Despotovic JM, Mortier NA, et al. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood. 2011;118(18):4985–4991.
   PubMed Web of Science ®Google Scholar
• Walker AL, Franke RM, Sparreboom A, et al. Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters. Exp Hematol. 2011;39(4):446–456.
   PubMed Web of Science ®Google Scholar
• Cokic VP, Andric SA, Stojilkovic SS, et al. Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells. Blood. 2008;111(3):1117–1123.
   PubMed Web of Science ®Google Scholar
• Park J-I, Choi HS, Jeong J, et al. Involvement of p38 kinase in hydroxyurea-induced differentiation of K562 cells. Cell Growth Differ. 2001;12(9):481–486.
   PubMedGoogle Scholar
• Solovieff N, Milton JN, Hartley SW, et al. Fetal hemoglobin in sickle cell anemia: genome-wide association studies suggest a regulatory region in the 5' olfactory receptor gene cluster. Blood. 2010;115(9):1815–1822.
   PubMed Web of Science ®Google Scholar
• Cohen-Barak O, Hagiwara N, Arlt MF, et al. Cloning, characterization and chromosome mapping of the human SOX6 gene. Gene. 2001;265(1–2):157–164.
   PubMed Web of Science ®Google Scholar
• Guth SI, Wegner M. Having it both ways: Sox protein function between conservation and innovation. Cell Mol Life Sci. 2008;65(19):3000–3018.
   PubMed Web of Science ®Google Scholar
• Li J, Shen J, Wang K, et al. The roles of Sox family genes in sarcoma. Curr Drug Targets. 2016;17(15):1761–1772.
   PubMed Web of Science ®Google Scholar
• Cohen-Barak O, Yi Z, Hagiwara N, et al. Sox6 regulation of cardiac myocyte development. Nucleic Acids Res. 2003;31(20):5941–5948.
   PubMed Web of Science ®Google Scholar
• Hagiwara N, Klewer S, Samson R, et al. Sox6 is a candidate gene for p100H myopathy, heart block, and sudden neonatal death. Proc Natl Acad Sci USA. 2000;97(8):4180–4185.
   PubMed Web of Science ®Google Scholar
• Connor F, Wright E, Denny P, et al. The SRY-related HMG box-containing gene Sox6 is expressed in the adult testis and developing nervous system of the mouse. Nucleic Acids Res. 1995;23(17):3365–3372.
   PubMed Web of Science ®Google Scholar
• Lee KE, Seo J, Shin J, et al. Positive feedback loop between Sox2 and Sox6 inhibits neuronal differentiation in the developing central nervous system. Proc Natl Acad Sci USA. 2014;111(7):2794–2799.
   PubMed Web of Science ®Google Scholar
• Smits P, Li P, Mandel J, et al. The transcription factors L-Sox5 and Sox6 are essential for cartilage formation. Dev Cell. 2001;1(2):277–290.
   PubMed Web of Science ®Google Scholar
• Hagiwara N, Yeh M, Liu A. Sox6 is required for normal fiber type differentiation of fetal skeletal muscle in mice. Dev Dyn. 2007;236(8):2062–2076.
   PubMed Web of Science ®Google Scholar
• Dumitriu B, Patrick MR, Petschek JP, et al. Sox6 cell-autonomously stimulates erythroid cell survival, proliferation, and terminal maturation and is thereby an important enhancer of definitive erythropoiesis during mouse development. Blood. 2006;108(4):1198–1207.
   PubMed Web of Science ®Google Scholar
• Yi Z, Cohen-Barak O, Hagiwara N, et al. Sox6 directly silences epsilon globin expression in definitive erythropoiesis. PLoS Genet. 2006;2(2):e14.
   PubMed Web of Science ®Google Scholar
• Xu J, Sankaran VG, Ni M, et al. Transcriptional silencing of γ-globin by BCL11A involves long-range interactions and cooperation with SOX6. Genes Dev. 2010;24(8):783–798.
   PubMed Web of Science ®Google Scholar
• Karimi M, Zarei T, Haghpanah S, et al. Relationship between some single-nucleotide polymorphism and response to hydroxyurea therapy in Iranian patients with β-thalassemia intermedia. J Pediatr Hematol/Oncol. 2017;39(4):e171–e.176.
   PubMed Web of Science ®Google Scholar
• Karimi M, Cohan N, De Sanctis V, et al. Guidelines for diagnosis and management of β-thalassemia intermedia. Pediatr Hematol Oncol. 2014;31(7):583–596.
   PubMed Web of Science ®Google Scholar
• Cario H, Wegener M, Debatin K-M, et al. Treatment with hydroxyurea in thalassemia intermedia with paravertebral pseudotumors of extramedullary hematopoiesis. Ann Hematol. 2002;81(8):478–482.
   PubMed Web of Science ®Google Scholar
• Koren A, Levin C, Dgany O, et al. Response to hydroxyurea therapy in β-thalassemia. Am J Hematol. 2008;83(5):366–370.
   PubMed Web of Science ®Google Scholar
• Ghasemi A, Keikhaei B, Ghodsi R. Side effects of hydroxyurea in patients with thalassemia major and thalassemia intermedia and sickle cell anemia. Iran J Pediatr Hematol Oncol. 2014;4(3):114–117.
   PubMedGoogle Scholar
• Karimi M, Darzi H, Yavarian M. Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. J Pediatr Hematol Oncol. 2005;27(7):380–385.
   PubMed Web of Science ®Google Scholar
• Karimi M, Cohan N, Moosavizadeh K, et al. Adverse effects of hydroxyurea in β-thalassemia intermedia patients: 10 years’ experience. Pediatr Hematol Oncol. 2010;27(3):205–211.
   PubMed Web of Science ®Google Scholar
• Taher AT, Musallam KM, Cappellini MD, et al. Optimal management of β thalassaemia intermedia. Br J Haematol. 2011;152(5):512–523.
   PubMed Web of Science ®Google Scholar
• Karimi M, Haghpanah S, Farhadi A, et al. Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. Int J Hematol. 2012;95(1):51–56.
   PubMed Web of Science ®Google Scholar
• Dixit A, Chatterjee TC, Mishra P, et al. Hydroxyurea in thalassemia intermedia-a promising therapy. Ann Hematol. 2005;84(7):441–446.
   PubMed Web of Science ®Google Scholar
• Panigrahi I, Dixit A, Arora S, et al. Do alpha deletions influence hydroxyurea response in thalassemia intermedia? Hematology. 2005;10(1):61–63.
   PubMed Web of Science ®Google Scholar
• Italia KY, Jijina FJ, Merchant R, et al. Response to hydroxyurea in β thalassemia major and intermedia: experience in western India. Clin Chim Acta. 2009;407(1–2):10–15.
   PubMed Web of Science ®Google Scholar
• Hashemi A, Abrishamkar M, Jenabzade AR, et al. Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia. Iran J Blood Cancer. 2009;1(4):147–150.
   Google Scholar